bio products laboratory
glassdoor has 13 bio products laboratory reviews submitted anonymously by bio products laboratory employees. read employee reviews and ratings on glassdoor to decide if bio products laboratory is right for you .
glassdoor gives you an inside look at what it' s like to work at bio products laboratory, including salaries, reviews, office photos, and more. this is the bio products laboratory company profile. all content is posted anonymously by employees working at bio products laboratory .
i applied online. the process took 6 weeks. i interviewed at bio products laboratory (elstree, england) in october 2017 .
bio products laboratory inc. (bpl) announces new vial size of gammaplex® for the treatment of primary immunodeficiency and chronic immune thrombocytopenic purpura
bio products laboratory (bpl) manufactures and distributes plasma - derived products, including intravenous immunoglobulin preparations, coagulation factors and albumin solution. the durham office is the u. s. distributor for bpl products .
former land o' lakes factory circa 1927 and current bio - techne corporate headquarters .
bio products laboratory ltd. (bpl) manufactures a wide range of plasma - derived therapeutic products which are distributed to over 40 countries worldwide. bpl is based in elstree, hertfordshire, and is part of bpl holdings which also operates a number of plasma centres in the usa .
elstree, hertfordshire, may 18, 2016 – bio products laboratory ltd. (“bpl”), a leading plasma biotherapeutics company, today announces that a group controlled by creat group corporation (“creat”), has signed a definitive agreement to acquire the company for a total cash consideration of £820 million .
t: + 44 (0) 208 258 2319, + 44 (0) 208 258 2249 | f: + 44 (0) 208 258 2689 | e: vacancies @ urltoken bio products laboratory ltd | dagger lane | elstree | hertfordshire | wd6 3bx | united kingdom registered no. 7343036
© bio products laboratory ltd. 2018, registered office: dagger lane, elstree, hertfordshire, wd6 3bx, united kingdom. tel: + 44 (0) 20 8957 2200 fax: + 44 (0) 20 8957 2601 email: info @ urltoken website: urltoken registered in england and wales, no. 7343036
it welcomed moves to protect the safety and supply of plasma products, but said people with haemophilia should urgently be given the safest treatment, which is synthetic genetically engineered recombinant products .
© 2017 bio products laboratory u. s. a. , inc. access to the professional medical secure section of the bpl website is possible by registering your correct medical qualifications and a relevant work placement / interest. those applying for access must be in professional medical employment or study. no attempt should be made to obtain access if not a member of a recognized medical professional organisation .
about bio products laboratory ltd. bpl is a leading manufacturer of plasma - derived protein therapies with global headquarters in elstree, england, us headquarters for its therapeutics operation in durham, nc. the company exports to more than 45 countries worldwide. bpl has over 60 years of experience developing and manufacturing plasma - derived therapies since being established as part of the lister institute in 1950, and currently markets a wide range of products including coagulation factors, human immunoglobulins, and albumin. bpl is committed to continued investment in research and development to maintain its key position as a reliable supplier of high - quality products to patients and healthcare providers worldwide .
today, our product line extends to over 24, 000 products, 95% of them manufactured in - house. while maintaining our core strengths in cytokines and immunoassays, we also develop antibodies, cell selection and multicolor flow cytometry kits, multiplex assays, biologically active compounds, and stem cell products and kits, as well as maintaining a clinical hematology laboratory with the most diversified instruments capabilities in the industry. the company brings its diverse expertise and the combined strengths of its product offerings to the research and diagnostic communities, providing the resources needed to advance life sciences research and support clinical breakthroughs .
at bpl, we are committed to providing a continuous supply of reliable, high quality plasma - derived products worldwide, supporting both healthcare professionals and patients every day .
in 1991, with the purchase of amgen' s biologicals and dx business, we obtained our first cytokine elisa assay kit cleared by the fda for clinical diagnostic use. in 1998, we purchased genzyme corporation' s research products business. this acquisition established us as the world' s leading supplier of research and diagnostic cytokine products .
bpl is committed to supporting both healthcare professionals and providing a continuous supply of reliable, high quality, life saving products to patients on a 24 / 7, 365 day a year basis .
bpl' s products are used to treat primary immune deficiencies but also to treat secondary immune deficiencies, coagulation disorders including hemophilia and von willebrand disease and neurological disorders in certain markets. for more information, visit urltoken
in the 1990s, we turned our focus to expanding our sales and distribution network. we purchased british bio - technology products ltd. and established it as our first european distributor, renaming the group r & d systems europe, ltd. r & d systems europe sells and distributes the company' s biotechnology products throughout europe, africa, and the middle east. as a result of growth in the european market, we opened a sales office, r & d systems gmbh, in germany in 1995. in 2007, r & d systems established its wholly owned subsidiary in the people’s republic of china, opening its warehouse and distribution center later that year in shanghai. the subsidiary provides warehousing, marketing, sales, and technical services for the growing chinese market. in 2011, r & d systems china established a sales subsidiary in hong kong .
whilst some of you are at bpl to advance your resume and bank balance you must remember that you have a moral duty to safeguard for future generations what is an important asset making life saving products not just for the uk but the world .
mr ng yuk, ceo of creat group corporation, said: “we have come to know the management team at bpl well in recent years and have the highest respect for what they have achieved. we believe we can help bpl achieve its growth ambitions through our long - term investment approach and our deep knowledge of this sector. our additional investment will create new highly skilled jobs in the uk, as well as increase the supply of important plasma biotherapeutic products for the uk and globally, serving the needs of patients who depend on these lifesaving products. ”
in 2013, we further strengthened our clinical controls division with the acquisition of bionostics, a world - leading developer and manufacturer of calibrators and controls for original equipment manufacturers. based in devens, massachusetts, the company specializes in products for use in critical care and point - of - care blood glucose and blood gas testing .
the people are great, especially the ones that have been with the company through thick and thin. the location is nice - greenbelt land, with a country park across the road for lunchtime walks. and the products that bpl makes are life saving so make a real difference to patients lives around the world. it has a good and interesting heritage, being established in 1954 .
also in april of 2011, r & d systems and r & d systems europe acquired tocris holdings limited and subsidiaries, a leading supplier of pharmacological reagents for life sciences research. tocris reagents include bioactive peptides and small molecules designed to modulate the activity of receptors, ion channels, and a range of intracellular signaling molecules. these products are of interest to biomedical researchers in a wide variety of disciplines .
we also made strategic acquisitions. in 2005, r & d systems acquired fortron bioscience, inc. , a developer and manufacturer of monoclonal and polyclonal antibodies, antigens, and other biological reagents. with this purchase, we also acquired biospacific, inc. , a worldwide supplier of immunological reagents to the commercial diagnostic industry and a company with skills in supporting customers collaboratively from feasibility testing to manufacturing. the acquisitions enhanced r & d systems' ability to serve the diagnostics industry. fortron was merged into r & d systems biotechnology division in july 2007. in april, 2011, r & d systems acquired the assets of boston biochem, inc. , a leading global developer and manufacturer of innovative ubiquitin - related research products. founded in 1997, boston biochem specializes in several related product lines for ubiquitin and ubiquitin - like proteins and associated enzymes, substrates, inhibitors, and kits. these specialized products facilitate and accelerate biomedical research and drug discovery efforts .
creat, a leading chinese investment group, will invest £100 million in bpl to expand production capacity of lifesaving therapies, develop new products and access new markets. bpl’s existing management team is staying with the company, which will remain headquartered in the uk. creat will support management’s ambition to transform bpl into a global life - sciences champion, serving more customers and patients in a greater number of markets around the world. creat is a long - term strategic investor with a track record of growing businesses and a deep knowledge of the plasma sector .
john perkins, ceo of bpl, said: “i am delighted by our achievements at bpl in recent years. we have transformed bpl into a growth company by investing in people, production capacity, and new products. ultimately, we have increased supply and introduced new therapies to better serve patients. creat and the management team share a common set of values and a vision of what bpl can become. creat is an ideal partner for bpl’s next phase of growth. the entire bpl management team is excited to be working with creat and is committed to the future of bpl. ”
r & d systems, a minnesota - based biological products company, started by producing hematology controls and calibrators for use in hospitals and clinics. in 1977, we introduced our first product, a platelet - rich - plasma control, and in 1981, we became the second manufacturer in the world to release a whole blood control with platelets. over the years, the clinical controls division (formerly r & d systems hematology) has continued to develop a variety of hematology controls. in the early 1980s, however, workers at r & d systems noted that a growth factor with diverse and intriguing properties had been identified in platelets. at this time we turned our attention to the possibility of producing the growth factor as a reagent for the research community .
doctype html public
- / / w3c / / dtd html 4. 0 transitional / / en
urltoken
the british government has spent nearly £50m buying up a private american firm in an attempt to secure a safe long - term supply of blood plasma for the nhs, the bbc has learnt .
britain cannot use its own supplies, because it is feared they may be contaminated by variant cjd, bbc radio 4' s today programme reported .
although the government has already taken a number of steps to minimise contamination - including importing plasma to treat haemophiliacs - it has been advised it needs to safeguard its supplies .
niall dickson, the bbc' s social affairs editor, said as part of the
unusual step
the company' s management would remain unchanged, but the firm would only provide plasma for the nhs .
recently, new collection companies in the us have been bought up by private suppliers and the uk government was advised its supplies could be threatened, our correspondent said .
back in august, it emerged the risk of the human form of bse being transmitted through blood transfusions might be considerably higher than previously thought .
tests at the institute of animal health revealed one in six animals given blood from sheep infected with a similar disease went on to develop the illness, suggesting there was an
appreciable
risk to humans .
plasma is the fluid in which red and white blood cells and platelets are carried round the body .
it is separated and frozen so it can be used to clot blood, provide antibodies and vital minerals in patients needing big blood transfusions .
it is also used for premature babies and children having heart surgery or liver transplants .
the us is seen as the only country able to supply the quantity of blood plasma needed in the nhs without the risk of vcjd .
the doh spokeswoman said :
it was felt in order to make sure there was enough plasma, the best thing to do was to actually buy the company and make sure the supply continues .
dr ian gibson, chairman of the commons science and technology committee, said he was
slightly nervous
about the move .
i need to be reassured that the source is bona fide and reliable .
i' m sure they do all the correct tests, but vcjd is a very difficult agent to nail down .
dr gibson said artificial blood may one day be the best way to prevent any risk of vcjd, but he warned that scientists still had a long way to go to perfect artificial supplies .
the haemophilia society said the government' s decision to purchase life resources was an incomplete response to its concerns about vcjd .
bain capital, lp is one of the world’s leading private multi - asset alternative investment firms with over $ 95 billion of assets under management that creates lasting impact for our investors, teams, businesses, and the communities in which we live. since our founding in 1984, we’ve applied our insight and experience to organically expand into several asset classes including private equity, credit, public equity, venture capital and real estate. we leverage our shared platform to capture cross - asset class opportunities in strategic areas of focus. with offices on four continents, our global team aligns our interests with those of our investors for lasting impact .
please log in to access your account information. if you have any questions regarding your account, please contact
bpl, headquartered in elstree, hertfordshire, provides lifesaving therapeutics for conditions related to immune deficiencies, bleeding disorders, and critical care. bpl’s plasma division, the largest supplier of us plasma to third parties, provides specialty and source plasma to manufacturers that also produce lifesaving therapies .
currently, bpl is 80% owned by bain capital private equity and 20% by the uk department of health. bpl’s board of directors is unanimously supportive of the proposed sale of the company to creat. under bain capital’s ownership, the company has been transformed from a loss - making business to a profitable one. more than £50 million has been invested in the business, over 750 new jobs have been created, including over 150 at its uk headquarters, and sales have increased by 58% .
about creat group corporation creat group corporation is a leading chinese investment group founded in 1992 that has significant expertise in the plasma industry. it invests in healthcare and pharmaceuticals, manufacturing, energy, finance, natural resources, and real estate. the company is based in beijing, china, with other offices in hong kong and shanghai .
the trademarks and logos above are used for reference purposes only, and are the property of their respective owners. no endorsement of bain capital is intended by the use of such trademarks .
© 2012 - 2016 bain capital, lp. the bain capital square symbol is a trademark of bain capital, lp. all rights reserved. privacy policy terms of use regulatory disclosures web fraud and phishing warning
html public
- / / w3c / / dtd xhtml 1. 0 transitional / / en
urltoken
bpl has a vibrant 60 - year heritage and is currently embarking on an ambitious programme of investment in research, technology and manufacturing methods to grow the business significantly over the next few years .
glassdoor will not work properly unless browser cookie support is enabled. learn how to enable cookies .
explore the many benefits of having a premium branded profile on glassdoor, like increased influence and advanced analytics .
changes won' t be saved until you sign up for an enhanced profile subscription .
long days canteen is not 24 / 7 yet but i' d love to see it when they eventually do it sometimes on days car park gets full and you have to use other facilities which are provided but it' s a 5 minute walk .
assessment day followed by interview the following week. assessment consisted of a combination of group tasks and tests. certain tasks were about ability to persuade others, others were practical demonstration of scientific working. maths assessment was straight forward .
copyright © 2008–2018, glassdoor, inc .
glassdoor
and logo are proprietary trademarks of glassdoor, inc .
your trust is our top concern, so companies can' t alter or remove reviews .
if you work hard you will be held back without any career progression if you duck out of the tasks required of your role and treat team members disrespectfully you get the hours and pay you want without question. no management within teams, bosses sit in the office and let departments turn into a mess as long as they get this bonuses they don' t care. management not interested in your well being hire too much dead weight workers that do not contribute
take care of the employees that work hard for you because soon your company will be full of dead weight with zero work ethic! eventually it will go down the pan .
the transition from public to private ownership with bain capital from the usa taking over a majority stake in 2013 has meant on the upside substantial investment but on the downside a major shift in culture which has been rocky at times. most of the senior leadership team have been brought in anew and seem to be at bpl to make their money before moving on. this has resulted in the loss of a lot of head knowledge and people who previously were good at their job and cared a lot about the company .
company currently in rapid growth phase; a new vision and opportunities opening up. company culture changing rapidly from public sector to a more modern and competitive mainstream pharma business .
new corporate culture has introduced multiple layers of management and a dog - eat - dog environment. opportunities for career development internally are a lot more limited now as most new senior roles are filled with external candidates .
keep staff on board your plans by giving internal talent the opportunity to grow alongside the company .
no career opportunities. top heavy. needs to be lean with minimum managerial posts .
this will replace the current featured review for targeted profile. are you sure you want to replace it ?
for inquiries related to this message please contact support. for sales inquiries, please visit urltoken
if you believe this to be in error, please confirm below that you are not a robot by clicking
i' m not a robot
below .
please make sure your browser supports javascript and cookies and that you are not blocking them from loading. for more information you can review the terms of service and cookie policy .
html public
- / / w3c / / dtd xhtml + rdfa 1. 0 / / en
urltoken
the ncbiotech company directory is maintained by life science intelligence at ncbiotech. for more information, contact research @ urltoken .
life science intelligence at ncbiotech strives to provide accurate and current data on the bioscience community in north carolina. you may reproduce the ncbiotech company directory site content for any legal purpose with proper attribution. attribution shall take the following form :
data provided by the north carolina biotechnology center, www. ncbiotech. org .
this website uses cookies to help us know a little bit about you, how you use our website and improve the browsing experience. you can find out what cookies we use, what they do and how you can disable them in our cookie policy. by browsing this website and closing this message, you consent to the use of cookies in accordance with our cookie policy unless you have disabled them .
we are a uk headquartered group which delivers life - saving treatments around the world for conditions related to immune deficiencies, bleeding disorders and critical care. these treatments are produced through complex transformation of plasma, which is collected from us donors in a number of us - based collection facilities .
start typing to retrieve search suggestions. when suggestions are available use up and down arrows to review and enter to select. continue typing to refine .
d - gam, human anti - d immunoglobulin 2, 500 iu, solution for injection .
d - gam, human anti - d immunoglobulin, 1, 500 iu, solution for injection .
this site uses cookies. by continuing to browse the site you are agreeing to our policy on the use of cookies. continue
* final gross price and currency may vary according to local vat and billing address. * your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. a link to download a pdf version of the drug profile will be included in your email receipt. adis is an information provider. we do not sell or distribute the pharmaceutical compounds written about in this database .
orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases .
oops, it looks like you don’t have a valid subscription to this content. to gain full access to the content and functionality of the adisinsight database try one of the following .
if you are a subscriber to this content then contact us at asktheexpert. adisinsight @ urltoken so we can help .
. the new 20 g vial size will offer improved choice and convenience for infusion nurses and pharmacists as fewer vials will be needed when 20 g or more gammaplex are infused. the new vial size can also save valuable storage space compared with two 10 g vials .
with the addition of the 20 g vial, gammaplex will be available in three sizes in the united states, including 5 g (100 ml), 10 g (200 ml) and 20 g (400 ml). the first supply of gammaplex in this new vial size is now available to order .
about gammaplex gammaplex is 5 percent liquid igiv stabilized with sorbitol that has a viscosity similar to human plasma. in the united states, gammaplex is indicated for replacement therapy in adults with primary humoral immunodeficiency (pi). gammaplex is also indicated for the treatment of adults with chronic immune thrombocytopenic purpura (itp) to raise platelet counts .
gammaplex is contraindicated in patients who have had a history of anaphylactic or severe systemic reactions to human immune globulin; a hereditary intolerance to fructose and infants with undiagnosed fructose intolerance; and iga deficient patients with antibodies to iga and a history of hypersensitivity .
gammaplex is derived from human plasma. the risk of virus transmission cannot be completely eliminated .
in 1985, we released our first research reagent, tgf - beta 1, becoming the first company in the world to produce this cytokine commercially. tgf - beta 1 acts as an extracellular signaling molecule that is produced by many cell types. it is involved in such processes as immune function, cell proliferation, and cell differentiation. following the launch of this product, we purified several other cytokines from natural sources and released them to the research market. of great interest to biomedical researchers, cytokines are specialized proteins mediating communication between cells. they have many biological activities including regulating developmental processes and orchestrating the immune response. in addition, unregulated cytokine activity has been linked to many diseases including cancer, cardiovascular disease, and inflammatory disorders .
ribbon structure of tgf - beta 1, an r & d systems product .
encouraged by success in the cytokine market, we formed the growth factor (now known as biotechnology) division in 1985 with the goal of producing and marketing a wide range of human cytokines through genetic engineering. recombinant dna technology offers several advantages over extraction of these proteins from natural sources, including lower production cost and potentially unlimited supply. in 1989, the biotechnology division began developing monoclonal and polyclonal antibodies to cytokines, and in 1990 we developed our first enzyme - linked immunosorbent assay (elisa) kit.
the bio products laboratory ( bpl ) is a company involved in the manufacture of human blood plasma products , located in elstree in the united kingdom . it is owned by the creat group , a chinese investment firm . before august 2016 , it had been owned by bain capital ( 80 % ) and the uk government ( 20 % ) via holding company plasma resources uk ltd . bpl is run as a commercial business and supplies plasma derived products to the national health service in the uk as well as to markets in 45 countries .
the bio products laboratory (bpl) is a company involved in the manufacture of human blood plasma products, located in elstree in the united kingdom. it is owned by the creat group, a chinese investment firm. before august 2016, it had been owned by bain capital (80 %) and the uk government (20 %) via holding company plasma resources uk ltd. bpl is run as a commercial business and supplies plasma derived products to the national health service in the uk as well as to markets in 45 countries.
the bio products laboratory (bpl) is a company involved in the manufacture of human blood plasma products, located in elstree in the united kingdom. it is owned by the creat group, a chinese investment firm. before august 2016, it had been owned by bain capital (80 %) and the uk government (20 %) via holding company plasma resources uk ltd. bpl is run as a commercial business and supplies plasma derived products to the national health service in the uk as well as to markets in 45 countries.